Zanubrutinib in Waldenström's Macroglobulinemia (WM) - The Phase 3 ASPEN Trial

 SLIDE KIT   12   06/2021

In the ASPEN trial, Zanubrutinib was associated with a complete response/very good partial response (CR/VGPR) rate of 28% compared with ibrutinib of 19% (P=0.09). No patient achieved a CR. Zanubrutinib demonstrated clinically meaningful advantages in safety and tolerability.


Rate this resource